What you'll learn in this expert session
The key finding from WHI was that MHT using synthetic progestins is associated with adverse health outcomes compared to estrogen alone. Body identical, TGA approved, MHT offers transdermal or oral estradiol in combination with oral micronized progesterone to provide proven benefits and maximum safety for menopausal women.
Learning Objectives:
- Recognise the symptoms and common concerns that are present in women prior to, around and following the menopause
- Compare the different treatment options for Menopausal Vasomotor symptoms (VMS) and Vulvovaginal atrophy (VVA) in terms of safety and effectiveness.
- Critique and compare the evidence base and governance of Bio-identical compounded Menopause hormonal treatment (MHT) and Body-identical MHT
About the Expert
Dr Rod Baber
Rod Baber is Professor of Obstetrics and Gynaecology at The University of Sydney and operates a specialist Gynaecology and Reproductive Endocrinology practice based on Sydney's lower north shore. He also heads the menopause and menstrual disorders clinic at Royal North Shore Hospital. Rod is a life member and Past President Australasian menopause Society as well as past President International Menopause Society where he is also Honorary Life Member. He is Editor-in-Chief of Climacteric, the journal of The International Menopause Society and is Associate Editor of ANZ Journal of Obstetrics and Gynaecology.
Course curriculum
-
1
How to complete this course
-
Instructions
-
-
2
Topic: Why and How You Should Use Body Identical MHT
-
Summary and learning objectives
-
Video presentation (20 mins)
-
Quiz: test your learning (10 mins)
-
-
3
Document your CPD here
-
CPD Documentation and Reflection Activity Tool
-
-
4
Feedback
-
Please let us know your thoughts
-